Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J P Kastelein

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
The Netherlands Journal of Medicine|August 16, 2003
The future of lipid-lowering therapy: the big pictureJ J P Kastelein
International Journal of Clinical Practice|December 15, 2005
Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemiaJ J P Kastelein, R R Sankatsing
International Journal of Clinical Practice|December 15, 2005
Achieving lipid goals in real life: the Dutch DISCOVERY studyA F E Bots, J J P Kastelein,
European Heart Journal|January 7, 2015
The year in cardiology 2014: preventionG De Backer, J J P Kastelein, U Landmesser
Journal of Inherited Metabolic Disease|November 10, 2009
Heterozygous familial hypercholesterolaemia in childhood: cardiovascular risk preventionA van der Graaf, J J P Kastelein, A Wiegman
Current Atherosclerosis Reports|February 18, 2016
Thyroid Hormone Mimetics: the Past, Current Status and Future ChallengesL P B Elbers, J J P Kastelein, B Sjouke
Diabetes, Obesity & Metabolism|October 11, 2007
Normalization of metabolic syndrome using fenofibrate, metformin or their combinationM Nieuwdorp, E S G Stroes, J J P Kastelein, et al.
Clinical Nephrology|April 26, 2005
The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritisR C Ozsoy, M G Koopman, J J P Kastelein, et al.
Atherosclerosis|December 17, 2002
Atorvastatin and the dyslipidemia of early renal failureR C Ozsoy, J J P Kastelein, L Arisz, et al.
Diabetes, Obesity & Metabolism|March 30, 2007
Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart diseaseJ S Rana, M Nieuwdorp, J W Jukema, et al.
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
The Netherlands Journal of Medicine|August 16, 2003
The future of lipid-lowering therapy: the big pictureJ J P Kastelein
International Journal of Clinical Practice|December 15, 2005
Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemiaJ J P Kastelein, R R Sankatsing
International Journal of Clinical Practice|December 15, 2005
Achieving lipid goals in real life: the Dutch DISCOVERY studyA F E Bots, J J P Kastelein,
European Heart Journal|January 7, 2015
The year in cardiology 2014: preventionG De Backer, J J P Kastelein, U Landmesser
Journal of Inherited Metabolic Disease|November 10, 2009
Heterozygous familial hypercholesterolaemia in childhood: cardiovascular risk preventionA van der Graaf, J J P Kastelein, A Wiegman
Current Atherosclerosis Reports|February 18, 2016
Thyroid Hormone Mimetics: the Past, Current Status and Future ChallengesL P B Elbers, J J P Kastelein, B Sjouke
Diabetes, Obesity & Metabolism|October 11, 2007
Normalization of metabolic syndrome using fenofibrate, metformin or their combinationM Nieuwdorp, E S G Stroes, J J P Kastelein, et al.
Clinical Nephrology|April 26, 2005
The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritisR C Ozsoy, M G Koopman, J J P Kastelein, et al.
Atherosclerosis|December 17, 2002
Atorvastatin and the dyslipidemia of early renal failureR C Ozsoy, J J P Kastelein, L Arisz, et al.
Diabetes, Obesity & Metabolism|March 30, 2007
Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart diseaseJ S Rana, M Nieuwdorp, J W Jukema, et al.
Pageof 9